Suppr超能文献

雄激素受体变体 AR-V7 的活性受到 FOXO1 的调控,这种调控方式依赖于 PTEN-PI3K-AKT。

The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way.

机构信息

Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA.

出版信息

Prostate. 2013 Feb 15;73(3):267-77. doi: 10.1002/pros.22566. Epub 2012 Jul 20.

Abstract

BACKGROUND

The androgen receptor (AR) AR-V7 splice isoform is a constitutively active outlaw transcription factor. Transition of prostate cancer (PC) to the castration-resistant phenotype correlates with AR-V7 accumulation, suggesting that PC progression in patients refractory to conventional therapy is due to the activity of this AR isoform. The mechanism of AR-V7 constitutive activation is not known.

METHODS

We analyzed potential signaling pathways associated with AR-V7 constitutive activation in PTEN (-) PC-3 and LNCaP cells. We used transient and stable transfection, reporter gene assay, RNAi technology together with a number of kinase inhibitors to determine if AR-V7 activation is linked to a kinase-dependent signaling pathway.

RESULTS

In these cell lines, AR-V7 transcriptional activity was inhibited by LY294002, Wortmanin, and AKT inhibitor II. Analysis of the contributing mechanisms demonstrated the involvement of the Phosphatidylinositol 3-kinase (PI3K)-AKT-FOXO1 signaling pathway, and a significant reduction of AR-V7 constitutive activity under conditions of PTEN reactivation.

CONCLUSIONS

Our study identifies a pathway regulating AR-V7 constitutive activity and potential therapeutic targets for the treatment of castration-resistant PC.

摘要

背景

雄激素受体 (AR) AR-V7 剪接异构体是一种组成型激活的非法转录因子。前列腺癌 (PC) 向去势抵抗表型的转变与 AR-V7 的积累相关,这表明在对常规治疗有抗药性的患者中,PC 的进展是由于这种 AR 异构体的活性。AR-V7 组成型激活的机制尚不清楚。

方法

我们分析了与 PTEN(-)PC-3 和 LNCaP 细胞中 AR-V7 组成型激活相关的潜在信号通路。我们使用瞬时和稳定转染、报告基因检测、RNAi 技术以及多种激酶抑制剂来确定 AR-V7 的激活是否与依赖激酶的信号通路有关。

结果

在这些细胞系中,LY294002、Wortmanin 和 AKT 抑制剂 II 抑制了 AR-V7 的转录活性。对促成机制的分析表明,磷酸肌醇 3-激酶 (PI3K)-AKT-FOXO1 信号通路的参与,以及在 PTEN 重新激活的条件下,AR-V7 组成型活性的显著降低。

结论

我们的研究确定了调节 AR-V7 组成型活性的途径,并为治疗去势抵抗性 PC 提供了潜在的治疗靶点。

相似文献

1
The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way.
Prostate. 2013 Feb 15;73(3):267-77. doi: 10.1002/pros.22566. Epub 2012 Jul 20.
2
Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.
PLoS One. 2014 Oct 31;9(10):e108780. doi: 10.1371/journal.pone.0108780. eCollection 2014.
3
FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants.
Prostate. 2013 Jul;73(10):1017-27. doi: 10.1002/pros.22649. Epub 2013 Feb 6.
4
Interplay Among PI3K/AKT, PTEN/FOXO and AR Signaling in Prostate Cancer.
Adv Exp Med Biol. 2019;1210:319-331. doi: 10.1007/978-3-030-32656-2_14.
7
Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer.
Cancer Res. 2009 Nov 1;69(21):8386-94. doi: 10.1158/0008-5472.CAN-09-1504. Epub 2009 Oct 13.
8
High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Eur Urol. 2015 Jun;67(6):1177-1185. doi: 10.1016/j.eururo.2014.08.053. Epub 2014 Sep 12.

引用本文的文献

1
Pleckstrin-2 Mediates the Activation of AKT in Prostate Cancer and Is Repressed by Androgen Receptor.
Am J Pathol. 2024 Oct;194(10):1986-1996. doi: 10.1016/j.ajpath.2024.07.004. Epub 2024 Jul 26.
2
Regulation of Molecular Biomarkers Associated with the Progression of Prostate Cancer.
Int J Mol Sci. 2024 Apr 10;25(8):4171. doi: 10.3390/ijms25084171.
3
Caffeic acid phenethyl ester suppresses the expression of androgen receptor variant 7 via inhibition of CDK1 and AKT.
Cancer Gene Ther. 2024 Jun;31(6):807-815. doi: 10.1038/s41417-024-00753-z. Epub 2024 Mar 13.
4
A compendium of Androgen Receptor Variant 7 target genes and their role in Castration Resistant Prostate Cancer.
Front Oncol. 2023 Mar 1;13:1129140. doi: 10.3389/fonc.2023.1129140. eCollection 2023.
5
The Crucial Role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant Prostate Cancer.
Cancers (Basel). 2022 Oct 5;14(19):4877. doi: 10.3390/cancers14194877.
8
Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.
Theranostics. 2021 Jan 1;11(2):958-973. doi: 10.7150/thno.51478. eCollection 2021.
10
Inositol polyphosphate 4-phosphatase type II regulation of androgen receptor activity.
Oncogene. 2019 Feb;38(7):1121-1135. doi: 10.1038/s41388-018-0498-3. Epub 2018 Sep 18.

本文引用的文献

2
Beefing up prostate cancer therapy with performance-enhancing (anti-) steroids.
Cancer Cell. 2011 Jul 12;20(1):7-9. doi: 10.1016/j.ccr.2011.06.019.
3
Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.
CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36. doi: 10.3322/caac.20121. Epub 2011 Jun 17.
4
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.
Cancer Cell. 2011 May 17;19(5):575-86. doi: 10.1016/j.ccr.2011.04.008.
5
Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma.
Clin Cancer Res. 2010 Dec 1;16(23):5692-702. doi: 10.1158/1078-0432.CCR-10-1601.
6
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.
Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16759-65. doi: 10.1073/pnas.1012443107. Epub 2010 Sep 7.
7
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.
J Clin Invest. 2010 Aug;120(8):2715-30. doi: 10.1172/JCI41824. Epub 2010 Jul 19.
9
Targeting the phosphoinositide 3-kinase pathway in cancer.
Nat Rev Drug Discov. 2009 Aug;8(8):627-44. doi: 10.1038/nrd2926.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验